Bird flu tops 2005 global health concerns
December 22, 2005Sales and Marketing
A survey conducted by the World Health Organisation has confirmed concerns over a possible bird flu pandemic as the year's …
Tamiflu-resistant bird flu found
December 22, 2005Sales and Marketing
A report of two cases of bird flu which proved resistant to treatment with Tamiflu have been reported in the …
FDA approves Bayer’s kidney cancer drug
December 22, 2005Sales and Marketing
Bayer's Nexavar has become the first treatment in more than ten years to receive approval in the US for the …
Pfizer lifted by Lipitor patent victory
December 20, 2005Sales and Marketing
Shares in Pfizer have risen after it saw off a patent challenge to Lipitor, its biggest selling drug.Lipitor generates around …
An Inspector Calls
December 20, 2005I have become a pharmacovigilance bore within my company – a prophet of doom. It is worse than that, because …
Right-sizing the salesforce
December 20, 2005Sales and Marketing salesforce
Can we form an impression about how good or ‘right’ a team is simply by the size of it? We …
Private sector vital for Government plans for patient choice
December 15, 2005NHS, private sector
Patients are to be given more choice in their care as the NHS undertakes an ambitious set of reforms intended …
Prexige wins approval in UK
December 15, 2005Sales and Marketing
Prexige has finally been launched in the UK after a safety review of the entire Cox-II class delayed its entrance …
Merck disappointed after jury undecided in Vioxx case
December 13, 2005Sales and Marketing
Merck said it was disappointed after a jury failed to reach a unanimous decision in the first federal court case …
AstraZeneca doubles trial size for stroke drug
December 13, 2005Research and Development AstraZeneca, stroke
Late stage clinical trials of AstraZeneca’s new stroke treatment have resumed after the company decided to double the number of …
US regulator looks to improve communication strategy
December 13, 2005Sales and Marketing
The FDA is investigating ways of improving its communication of the risks, including dangerous side-effects, linked with prescription drugs.The US …
Seven Stones wins General Electric Healthcare account
December 13, 2005Medical Communications
Specialist healthcare communications agency Seven Stones has secured a new global account with General Electric Healthcare Discovery Systems.A subsidiary of …
Shire and New River expect new ADHD launch in 2006
December 8, 2005Sales and Marketing
New River Pharmaceuticals has filed a new treatment for attention deficit hyperactivity disorder (ADHD) with US regulator the FDA.New River …
350 million needed for stem cell research
December 8, 2005Research and Development
At least £350 million extra funding is needed for UK stem cell research if it is to maintain its international …
J&J submits new schizophrenia drug
December 8, 2005Sales and Marketing
Johnson & Johnson has submitted a new schizophrenia drug to the FDA, and hopes it will succeed one of its …
McKillop calls for changes to EU pharmaceutical market
December 8, 2005Research and Development
AstraZeneca's chief executive Sir Tom McKillop says action is needed on pricing and the clinical trials environment in order to …
Brooksby to be new ABPI president
December 8, 2005Sales and Marketing
Nigel Brooksby, Sanofi-Aventis UK's managing director has been named as the ABPI's next president.Brooksby will take over from the current …
Merck seeks US approval for cancer vaccine
December 7, 2005Sales and Marketing
Merck has submitted its cervical cancer vaccine Gardasil to the FDA following impressive clinical trial results against the two most …
Can CSOs lead the way?
December 7, 2005Sales and Marketing
With the spotlight shining on pharma sales teams, companies are exploring a variety of ways to improve productivity and effectiveness. …
Pharmacies offer lab tests for long-term conditions
December 7, 2005Up to 6,000 patients could benefit from a new pilot project which will see high street pharmacies providing lab tests …
Latest content
FibroFind appoints Lee Borthwick as CEO
